Westhampton Capital LLC Grows Stock Position in Thermo Fisher Scientific Inc. $TMO

Westhampton Capital LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,413 shares of the medical research company’s stock after purchasing an additional 168 shares during the quarter. Westhampton Capital LLC’s holdings in Thermo Fisher Scientific were worth $978,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Mondrian Investment Partners LTD increased its holdings in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after acquiring an additional 127,357 shares in the last quarter. Foresight Group Ltd Liability Partnership increased its holdings in Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after acquiring an additional 56,747 shares in the last quarter. Advisors Capital Management LLC boosted its stake in Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after purchasing an additional 7,967 shares during the period. New England Research & Management Inc. boosted its stake in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock worth $1,033,000 after purchasing an additional 567 shares during the period. Finally, IMS Capital Management bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $343,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.5%

Shares of TMO opened at $461.95 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $620.00. The company has a market cap of $174.44 billion, a PE ratio of 26.72, a P/E/G ratio of 2.52 and a beta of 0.75. The business has a fifty day moving average of $477.84 and a 200 day moving average of $446.71. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TMO shares. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. UBS Group raised their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $588.35.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.